Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maki Komiyama

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
European Cardiology|September 18, 2020
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced AwarenessMaki Komiyama, Koji Hasegawa
European Cardiology|October 13, 2018
<i>ISCP Guest Editorial</i>: Cardiovascular Disease Prevention in DiabetesMaki Komiyama, Koji Hasegawa
European Cardiology|May 7, 2020
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 PandemicMaki Komiyama, Koji Hasegawa
European Cardiology|October 4, 2021
Coronavirus Disease 2019: Psychological Stress and Cardiovascular DiseasesMaki Komiyama, Koji Hasegawa
European Cardiology|August 4, 2020
Response to the Comment 'Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019Maki Komiyama, Koji Hasegawa
European Cardiology|March 14, 2022
European Society of Cardiology Highlights: Late-breaking Trials - COVID-19Maki Komiyama, Koji Hasegawa
European Cardiology|May 28, 2019
Obesity and Cardiovascular Risk After Quitting Smoking: The Latest EvidenceKoji Hasegawa, Maki Komiyama, Yuko Takahashi
Internal Medicine (Tokyo, Japan)|April 18, 2014
Matters of controversy regarding lipid therapy for Japanese patients with coronary artery diseaseMaki Komiyama, Hiromichi Wada, Koji Hasegawa
European Cardiology|June 16, 2020
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?Maki Komiyama, Koji Hasegawa, Akira Matsumori
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2022
Future of antithrombotic therapy for heart failure with coronary artery diseaseMaki Komiyama, Stefan Agewall, Koji Hasegawa
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
European Cardiology|September 18, 2020
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced AwarenessMaki Komiyama, Koji Hasegawa
European Cardiology|October 13, 2018
<i>ISCP Guest Editorial</i>: Cardiovascular Disease Prevention in DiabetesMaki Komiyama, Koji Hasegawa
European Cardiology|May 7, 2020
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 PandemicMaki Komiyama, Koji Hasegawa
European Cardiology|October 4, 2021
Coronavirus Disease 2019: Psychological Stress and Cardiovascular DiseasesMaki Komiyama, Koji Hasegawa
European Cardiology|August 4, 2020
Response to the Comment 'Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019Maki Komiyama, Koji Hasegawa
European Cardiology|March 14, 2022
European Society of Cardiology Highlights: Late-breaking Trials - COVID-19Maki Komiyama, Koji Hasegawa
European Cardiology|May 28, 2019
Obesity and Cardiovascular Risk After Quitting Smoking: The Latest EvidenceKoji Hasegawa, Maki Komiyama, Yuko Takahashi
Internal Medicine (Tokyo, Japan)|April 18, 2014
Matters of controversy regarding lipid therapy for Japanese patients with coronary artery diseaseMaki Komiyama, Hiromichi Wada, Koji Hasegawa
European Cardiology|June 16, 2020
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?Maki Komiyama, Koji Hasegawa, Akira Matsumori
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2022
Future of antithrombotic therapy for heart failure with coronary artery diseaseMaki Komiyama, Stefan Agewall, Koji Hasegawa
Pageof 6